CymaBay Therapeutics Inc. (NASDAQ:CBAY) Director Kurt Von Emster sold 50,048 shares of the firm’s stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $9.26, for a total transaction of $463,444.48. Following the transaction, the director now owns 90,000 shares of the company’s stock, valued at approximately $833,400. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Kurt Von Emster also recently made the following trade(s):

  • On Tuesday, October 31st, Kurt Von Emster sold 59,209 shares of CymaBay Therapeutics stock. The stock was sold at an average price of $9.27, for a total transaction of $548,867.43.
  • On Tuesday, October 3rd, Kurt Von Emster sold 108,876 shares of CymaBay Therapeutics stock. The stock was sold at an average price of $7.85, for a total transaction of $854,676.60.
  • On Friday, September 29th, Kurt Von Emster sold 211,124 shares of CymaBay Therapeutics stock. The stock was sold at an average price of $8.09, for a total transaction of $1,707,993.16.

Shares of CymaBay Therapeutics Inc. (CBAY) opened at $8.52 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 7.39 and a current ratio of 7.39. CymaBay Therapeutics Inc. has a one year low of $1.46 and a one year high of $9.40.

CymaBay Therapeutics (NASDAQ:CBAY) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02). During the same quarter in the prior year, the company posted ($0.25) EPS. research analysts expect that CymaBay Therapeutics Inc. will post -0.84 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “CymaBay Therapeutics Inc. (CBAY) Director Sells $463,444.48 in Stock” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/11/17/cymabay-therapeutics-inc-cbay-director-sells-463444-48-in-stock.html.

Several research analysts have issued reports on the stock. Cantor Fitzgerald restated a “buy” rating and set a $16.00 price target on shares of CymaBay Therapeutics in a report on Wednesday, November 8th. Oppenheimer Holdings, Inc. set a $15.00 price target on shares of CymaBay Therapeutics and gave the stock a “buy” rating in a report on Monday, October 30th. Piper Jaffray Companies restated a “buy” rating and set a $12.00 price target on shares of CymaBay Therapeutics in a report on Friday, October 27th. Zacks Investment Research upgraded shares of CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, September 18th. Finally, Leerink Swann assumed coverage on shares of CymaBay Therapeutics in a research note on Wednesday, August 23rd. They issued an “outperform” rating and a $12.00 price objective for the company. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. CymaBay Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $14.00.

Several large investors have recently added to or reduced their stakes in CBAY. Ardsley Advisory Partners increased its stake in CymaBay Therapeutics by 66.2% during the 2nd quarter. Ardsley Advisory Partners now owns 50,210 shares of the biopharmaceutical company’s stock valued at $290,000 after purchasing an additional 20,000 shares in the last quarter. Marshall Wace North America L.P. bought a new stake in CymaBay Therapeutics during the 2nd quarter valued at $242,000. Bank of New York Mellon Corp increased its stake in CymaBay Therapeutics by 0.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 17,344 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 140 shares in the last quarter. Omega Fund Management LLC increased its stake in CymaBay Therapeutics by 82.9% during the 3rd quarter. Omega Fund Management LLC now owns 551,477 shares of the biopharmaceutical company’s stock valued at $4,445,000 after purchasing an additional 250,000 shares in the last quarter. Finally, Crestline Management LP bought a new stake in CymaBay Therapeutics during the 3rd quarter valued at $841,000. Institutional investors own 27.08% of the company’s stock.

CymaBay Therapeutics Company Profile

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Insider Buying and Selling by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Stock Ratings for CymaBay Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc. and related stocks with our FREE daily email newsletter.